challeng
concept
idiopath
parkinson
ip
inevit
progress
neurodegener
propos
natur
histori
sequenti
microbi
insult
predispos
host
respons
proofofprincipl
infect
contribut
ip
provid
case
studi
placebocontrol
efficaci
studi
helicobact
erad
malign
ip
appear
convert
benign
mark
deterior
accompani
failur
similar
benefit
bradi
hypokinesia
erad
lowdens
infect
favor
autoimmun
although
minor
uk
proband
urea
breath
test
posit
helicobact
predict
probabl
parkinsonian
label
depend
serum
h
pylori
antibodi
profil
clinic
relev
gradient
discrimin
index
diseas
burden
progress
ip
h
pylori
antibodi
discrimin
persist
abnorm
bowel
function
specif
abnorm
duoden
enterocyt
mitochondri
morpholog
describ
relat
h
pylori
infect
slow
intestin
transit
manifest
constip
prodrom
diarrhea
may
flag
secondari
smallintestin
bacteri
overgrowth
coupl
genet
determin
intens
inflammatori
respons
might
explain
evolut
bradyhypokinet
rigiditypredomin
parkinson
infect
aetiologypathogenesi
pd
dobb
et
al
jame
parkinson
describ
shake
palsi
rigid
bradyhypokinet
syndrom
characterist
tremor
stoop
postur
consequ
therapeut
mileston
far
note
wider
antiparkinsonian
effect
tinctur
deadli
nightshad
use
control
excess
saliv
describ
dopamin
defici
basal
ganglia
therebi
instig
dopaminesubstitut
therapi
discov
antiparkinsonian
effect
antivir
agent
amantadin
way
helicobact
etiolog
hypothesi
pave
discoveri
h
pyloriassoci
gastriti
observ
excess
previous
document
peptic
ulcer
parkinson
diseas
specul
infecti
agent
involv
explicit
suggest
causal
link
follow
presenc
intracytoplasm
inclus
lewi
bodi
characterist
distribut
brain
recent
consid
gold
standard
design
parkinson
diseas
howev
whittl
away
popul
syndrom
core
sampl
accord
clinic
predictor
postmortem
brain
histopatholog
tenabl
start
point
unravel
causal
syndrom
manifest
system
diseas
unifi
patholog
would
expect
outsid
brain
moreov
age
brain
frequent
affect
one
neurodegen
patholog
parkinsonian
alzheim
often
coexist
polymorph
singl
gene
associ
parkinson
alon
distinct
neurolog
phenotyp
one
type
patholog
hallmark
even
neuron
environment
insult
might
also
result
neuron
deposit
differ
aberr
protein
spectrum
associ
phenotyp
use
caln
broad
clinic
definit
idiopath
parkinson
ip
describ
syndrom
unknown
etiolog
regard
manifest
net
effect
dose
genet
predisposit
environment
risk
factor
balanc
vari
betweenand
withinproband
howev
convinc
evid
ip
excess
exposur
environment
chemic
studi
gene
control
metabol
unreward
strategi
approach
led
infect
hypothesi
implic
gut
see
defin
assembl
jigsaw
piec
tabl
initi
therapeut
target
smallintestin
bacteri
overgrowth
sibo
secondari
slow
transit
inde
constip
featur
jame
parkinson
essay
ip
frequenc
defec
begin
deviat
control
three
decad
median
age
neurolog
diagnosi
two
diagnosi
tabl
gener
infect
hypothesi
idiopath
parkinson
ip
implic
gut
statist
model
find
observ
comparison
nocturn
axial
rotat
elderli
ip
proband
spous
control
coupl
rotat
spous
less
control
greater
proband
comparison
measur
facet
parkinson
elderli
proband
spous
control
coupl
spous
significantli
differ
control
toward
parkinson
measur
bradyhypokinesia
postur
abnorm
rigid
frequenc
seborrh
dermat
relationship
serum
immunoglobulin
concentr
presenc
absenc
overal
differ
igm
g
ip
b
ii
control
bradykinesia
associ
higher
iga
lower
postur
abnorm
higher
iga
exagger
age
diagnos
ip
ii
parkinsonian
featur
subject
without
diagnos
parkinson
iii
specifi
medic
ip
proband
iii
iga
higher
proband
constip
warrant
lax
take
antimuscarin
c
higher
iga
ii
iii
explain
subclass
system
rather
mucos
respons
comparison
ip
proband
control
current
estim
past
frequenc
defec
frequenc
less
proband
prodrom
fourth
decad
life
ii
associ
serum
iga
discrimin
index
presenc
absenc
parkinson
base
current
bowel
habit
ii
iga
increas
index
irrespect
subject
group
iii
differenti
effect
smoke
difficulti
pass
motion
laxativelik
effect
greater
control
iii
rel
effect
tobacco
smoke
bowel
habit
comparison
serum
cortisol
ip
proband
control
take
account
current
past
smoke
ii
antiparkinsonian
medic
lax
ip
cortisol
higher
ip
control
lower
cortisol
shorter
stride
deterior
year
relationship
invert
ip
smoke
tend
associ
lower
cortisol
irrespect
group
ii
levodopa
dopaminerg
agonist
affect
cortisol
selegilin
antimuscarin
reduc
constip
warrant
lax
tend
increas
comparison
serum
ip
proband
control
increas
age
effect
ip
equival
year
age
first
quartil
proband
find
upheld
prospect
associ
infrequ
bowel
movement
subsequ
diagnosi
parkinson
ip
loss
damag
colon
myenter
dopaminerg
neuron
enter
plexu
ganglia
physiolog
relat
sympathet
neuron
contain
lewi
bodi
dorsal
vagal
nucleu
pfeiffer
think
similar
noninfect
line
home
constip
marker
genesi
ip
collater
hypothesi
tabl
describ
epidemiolog
fit
helicobact
infect
ip
includ
famili
cluster
evid
earli
acquisit
long
prodrom
associ
water
sourc
propos
autoimmun
basi
proof
principl
infect
contribut
ip
case
studi
antihelicobact
therapi
gastriti
without
associ
helicobact
hypothesistest
studi
essenc
malign
ip
appear
convert
benign
follow
success
erad
mark
deterior
accompani
failur
case
late
ip
erad
helicobact
produc
uturn
parkinson
cachexia
proband
receiv
stabl
longt
antiparkinsonian
medic
random
efficaci
studi
contrast
effect
time
cours
ip
facet
week
success
antih
pylori
therapi
placebo
failur
improv
primari
outcom
mean
stride
length
freewalk
speed
follow
success
blind
activ
therapi
deblind
schedul
year
postrandom
benefit
bradyhypokinesia
fall
year
deblind
echo
given
openact
antih
pylori
therapi
subsequ
placebo
improv
irrespect
whether
patient
yet
receiv
background
antiparkinsonian
medic
figur
illustr
gait
improv
dramat
follow
h
pylori
erad
therapi
biopsi
molecular
microbiolog
posit
cultur
neg
evid
sibo
infect
lowdens
infect
may
suffici
perpetu
autoimmun
persist
even
level
detect
appear
detriment
howev
see
diseas
modif
cure
time
trend
object
measur
facet
parkinson
dissoci
follow
h
pylori
erad
insidi
increas
rigid
mirror
imag
pattern
hypokinesia
mean
torqu
requir
extend
relax
forearm
increas
follow
success
blindedact
therapi
compar
placebo
irrespect
antiparkinsonian
medic
statu
echo
given
openact
size
effect
clinic
relev
compar
baselin
measur
step
back
peptic
ulcer
presum
zenith
gastric
inflammatori
respons
helicobact
preced
diagnosi
ip
often
decad
uk
ip
proband
serum
h
pylori
immunoblot
posit
urea
breath
test
posit
immunoblot
posit
directli
relat
blood
lymphocyt
count
lymphopenia
featur
ip
irrespect
evid
current
helicobact
infect
serum
immunoblot
antibodi
profil
predict
presenc
sever
ip
also
progress
year
contrast
peptic
ulcer
clinic
manifest
slow
gastrointestin
transit
becom
appar
postdiagnosi
h
pylori
immunoblot
predict
abnorm
bowel
function
within
ip
irrespect
current
infect
helicobact
associ
autoimmun
might
wrought
irrepar
damag
enter
nervou
system
sixti
percent
proband
without
current
helicobact
infect
lactulosehydrogen
breath
test
posit
sibo
obviou
benefit
accru
helicobact
erad
loss
hypersecret
respons
antral
gastriti
may
weaken
gastric
acid
barrier
make
condit
sibo
opportun
stage
accommod
variabl
proband
manifest
ip
within
subject
chang
predomin
manifest
stage
fig
propos
helicobact
infect
evok
autoimmun
mitochondria
mechan
underli
bradi
hypokinesia
predomin
ip
helicobact
infect
transmit
close
contact
parent
sibl
infant
accord
younger
child
parent
develop
ip
greater
risk
ip
child
proband
sibl
share
facet
syndrom
increas
preval
h
pylori
seroposit
younger
peopl
preval
urea
breath
test
posit
fall
associ
better
hygieneincreas
exposur
antimicrobi
incid
agespecif
mortal
ip
howev
transient
h
pylori
infect
persist
low
densiti
may
suffici
triggerperpetu
autoimmun
therebi
set
scene
agespecif
increas
ip
older
peopl
propos
stage
acquisit
sibo
caus
mitochondri
dysfunct
result
rigiditypredomin
pictur
chronic
infect
larg
mucos
interfac
ratchet
doserel
mitochondri
damag
potenc
magnifi
polymorph
intens
innat
inflammatori
respons
adapt
immunodefici
might
predispos
sibo
earli
case
studi
show
improv
rigid
erad
sibo
lactulosehydrogen
breath
test
criterion
reinfectionrecrudesc
probabl
stage
may
tabl
gener
helicobact
hypothesi
idiopath
parkinson
ip
year
statist
model
find
observ
comparison
facet
parkinson
h
pylori
antiureas
elisa
seroposit
ip
proband
sibl
control
sibl
significantli
differ
control
toward
parkinson
measur
bradyhypokinesia
rigid
abnorm
postur
frequenc
seborrheaseborrh
dermat
odd
ratio
seroposit
proband
sibl
cf
control
explan
facet
syndrom
h
pylori
ureas
antibodi
subject
without
diagnos
parkinson
seroposit
unrel
presenceabs
facet
pass
diagnost
threshold
decreas
abnorm
postur
ip
b
relationship
increas
serum
age
cortisol
parkinson
h
pylori
ureas
antibodi
immuneinflammatori
respons
explain
antibodi
measur
routin
elisa
explan
increas
serum
cortisol
ip
control
presenceabs
antibodi
vaca
caga
ureaseb
effect
antibodi
independ
diseas
statu
antivaca
seroposit
associ
elev
cortisol
ip
addit
elev
neither
antiureas
anticaga
ad
varianc
explain
contrast
relationship
h
pylori
ureas
antibodi
age
subject
without
diagnos
parkinson
birthcohort
effect
elisa
valu
ev
seen
control
obliter
ip
proband
twice
like
seroposit
year
ii
relationship
titer
sever
ip
ii
ev
lower
greater
global
diseas
sever
b
contrast
relationship
serum
immunoglobulin
class
h
pylori
ureas
antibodi
subject
without
diagnos
parkinson
control
downward
shift
igm
antiureas
posit
equival
year
age
ip
igm
higher
control
seroposit
c
lower
seroneg
seroposit
effect
iga
igg
either
group
discrimin
seborrh
dermat
h
pylori
serum
immunoblot
antibodi
profil
subject
without
diagnos
parkinson
discrimin
index
presenc
characterist
rash
contain
anticaga
directli
associ
antivaca
invers
e
contrast
relationship
underweight
inflammatori
product
subject
without
diagnos
parkinson
associ
low
bodi
mass
index
serum
concentr
specif
parkinson
unlik
antivaca
anticaga
explan
failur
helicobact
erad
ip
blood
lymphocyt
subset
count
fail
erad
associ
lower
bcell
count
comparison
blood
count
ip
proband
spous
routin
gener
practition
request
total
lymphocyt
count
spous
untreat
proband
similar
lower
control
higher
count
proband
spous
vaca
antibodi
count
ip
explain
serum
folat
proband
count
lower
spous
higher
f
discrimin
parkinson
explan
sever
progress
h
pylori
serum
immunoblot
antibodi
profil
predict
probabl
label
parkinsonian
greatest
anticaga
seroposit
antivaca
ureaseb
neg
e
clinicallyrelev
associ
index
measur
diseas
facet
progress
ip
despit
potenti
confound
effect
antiparkinsonian
medic
discrimin
abnorm
bowel
function
constip
andor
diarrhea
ip
proband
spous
h
pylori
serum
immunoblot
profil
bowel
function
abnorm
proband
spous
fourfold
increas
odd
abnorm
function
ureaseb
band
sixfold
decrement
outermembran
protein
band
irrespect
urea
breath
test
statu
natur
abnorm
subject
group
irrit
bowel
syndrom
band
associ
contrast
elisa
seroposit
increas
older
spous
unpublish
data
b
h
pylori
antigen
ureas
known
stimul
cytokin
product
like
serum
immunoglobulin
class
may
associ
facet
parkinson
prodromeearli
diseas
helicobact
infect
like
forerunn
postur
abnorm
global
sever
ip
protect
c
although
count
low
may
increas
bcell
cell
produc
polyspecif
igm
altern
local
sequestr
igm
may
fail
ip
system
basal
ganglia
nigrostriat
immun
activ
ip
whilst
local
brain
inflamm
usual
signal
system
inflamm
commun
brain
immun
system
commun
involv
immun
cell
antibodi
inflammatori
product
occur
blood
brain
barrier
natur
defici
permeabl
increas
circul
cytokin
cortisol
peripher
affer
nerv
stimul
includ
vagal
activ
microglia
brain
resid
macrophag
helicobact
infect
could
stimul
vagu
sibo
perhap
peripher
infect
would
increas
traffic
signal
brain
substantia
nigra
regard
particularli
vulner
everyday
insult
product
dopamin
oxid
homeostat
mechan
function
full
stretch
nigral
glial
activ
would
increas
stress
recruit
immun
cell
local
mitochondri
dysfunct
describ
substantia
nigra
ip
complex
multiplesystem
atrophi
complex
iv
platelet
ip
inde
cybrid
cell
contain
mitochondri
platelet
nuclear
dna
donor
without
ip
respect
reduc
complex
activ
evid
system
extraneuron
mitochondri
involv
ip
filament
array
encapsul
doubl
membran
duoden
enterocyt
fig
upper
panel
found
among
normal
mitochondria
ip
proband
current
recent
h
pylori
infect
electron
microscopist
previous
observ
similar
bodi
although
two
exampl
found
subsequ
archiv
duoden
biopsi
patient
human
immunodefici
viru
hiv
infect
hiv
associ
parkinsonian
featur
isol
report
similar
mitochondri
inclus
cerebr
neuron
creutzfeldtjakoblik
diseas
prion
tubulovesicular
structur
larger
cluster
free
within
cytoplasm
found
prion
infect
site
outsid
central
nervou
system
routin
antimitochondri
antibodi
serolog
neg
ip
patient
unpublish
observ
cytoplasm
fluoresc
assay
may
detect
mitochondri
surfac
bind
autoimmun
ip
may
direct
mitochondri
protein
neoantigen
dna
rna
chromatin
matrilin
inherit
typic
mitochondri
disord
rare
parkinson
absenc
mitochondri
dna
repair
enzym
give
suscept
mutagen
modern
mitochondri
proteom
wide
accept
origin
part
endosymbiont
bacteria
helicobact
dna
might
incorpor
host
mitochondria
despit
evid
occurr
bacteriophag
h
pylori
transduct
demonstr
evid
conjugationlik
mechan
natur
transform
bacteria
helicobact
infect
may
trigger
proinflammatori
cytokin
tumour
necrosi
factor
tnf
intensifi
mitochondri
damag
long
thin
mitochondria
sometim
complex
branch
becom
predomin
featur
proband
duoden
enterocyt
subsequ
h
pylori
infect
presenc
sibo
fig
lower
panel
appar
hypertrophi
associ
rough
endoplasm
reticulum
may
compens
hypofunct
genet
determin
intens
system
innat
inflammatori
respons
would
acceler
natur
histori
ip
fig
howev
intens
respons
could
caus
helicobact
selfdestruct
protect
ureas
continu
produc
ammonia
face
power
inhibit
gastric
acid
secret
could
explain
lowdens
infect
gastric
atrophi
ip
increas
suscept
sibo
certain
polymorph
increas
risk
noncardiac
cancer
seroposit
antibodi
caga
geneproduct
escal
variabl
time
cours
ip
may
determin
analog
exploratori
studi
ip
suggest
greater
preval
similar
polymorph
associ
earli
onset
anticaga
seroposit
bad
prognost
sign
mild
acquir
adapt
immunodefici
flag
later
ip
lymphopenia
may
attenu
inflammatori
respons
may
doubleedg
guard
parkinsonian
effect
chronic
inflamm
leav
proband
open
infect
quieter
diseas
usual
old
age
tobacco
smoke
protect
parkinson
ulcer
coliti
may
immunomodulatori
pharmacolog
effect
injuri
physiolog
serum
cortisol
elev
lax
action
higher
preval
h
pyloriseroposit
smoker
irrespect
ip
might
keep
sibo
bay
ip
shift
ipoverlap
diseas
appropri
nosolog
group
seem
import
unravel
system
mitochondri
disord
may
give
spectrum
function
bowel
diseas
alon
comanifest
parkinson
fig
intens
natur
inflammatori
respons
primarili
betweensubject
determin
acquir
inherit
vulner
basal
ganglia
suscept
factor
scheme
possibl
pragmat
test
grew
exploratori
strategi
approach
differ
clinic
clue
address
differ
question
assess
balanc
probabl
tabl
aim
scientif
plausibl
etiolog
fit
oversight
interpret
given
statist
model
within
seri
jeopard
whole
particular
hierarch
layer
model
address
biolog
gradient
measur
ip
marker
inflamm
higher
serum
cortisol
detriment
ip
compar
control
serum
cortisol
interleukin
il
elev
overal
ip
associ
low
bodi
mass
index
increas
circul
specif
parkinson
contrast
healthi
control
cachexia
ip
usual
intract
associ
rapid
deterior
helicobact
infect
found
gastriti
sever
success
treatment
produc
turnabout
bodi
mass
index
normal
evid
helicobact
raven
appetit
night
sweat
common
may
larg
attribut
sibo
classic
spousal
approach
environment
causal
use
figur
illustr
short
highli
signific
distanc
pathway
spous
cohabit
ip
proband
half
centuri
mark
multifari
relev
differ
physiologicpsychomotordermatolog
spous
control
coupl
difficult
explain
select
mate
learnedreact
behavior
lymphopenia
larg
group
proband
spous
suggest
adult
transmiss
moreov
half
latter
proband
third
spous
chronic
bowel
abnorm
criteria
seven
percent
proband
spous
diarrhea
unform
stool
least
threequart
past
year
plu
three
bowel
movementsday
half
neuron
damag
proband
may
evad
diarrheal
respons
share
insult
biolog
gradient
measur
ip
serum
h
pylori
immunobot
antibodi
profil
strengthen
case
causal
control
without
diagnos
parkinson
relationship
suggest
undefin
bacteri
pathogen
host
suscept
factor
inde
doublemembran
bodi
contain
filament
array
duoden
enterocyt
might
flag
cours
parkinson
associ
h
pylori
immunoblot
profil
abnorm
bowel
function
within
ip
seborrh
dermat
frequent
accompani
ip
subject
without
parkinson
implic
helicobact
increas
preval
h
pylori
antiureas
seroposit
age
typic
gener
popul
socioeconom
advanc
countri
birth
cohort
effect
said
reflect
greater
earli
life
acquisit
persist
infect
less
hygien
time
ip
increas
preval
antiureas
seroposit
old
age
allow
signific
age
effect
captur
antiureas
titer
despit
demonstr
birth
cohort
effect
contemporan
control
lack
birth
cohort
effect
also
document
peptic
ulcer
gastric
carcinoma
causal
link
h
pylori
gener
accept
ip
also
differenti
trend
total
serum
igm
concentr
relat
antiureas
titer
h
pylori
cultur
supernat
whole
bacteria
protein
product
h
pylorispecif
regulatori
tlymphocyt
inhibit
human
tcell
prolifer
sinc
lymphopenia
ip
mark
h
pylori
immunoblot
neg
unlik
due
direct
inhibit
might
relat
helicobactertrigg
autoimmun
unlik
effect
platelet
idiopath
thrombocytopen
purpura
h
pylori
erad
littl
impact
ip
lymphopenia
mitochondri
damag
ip
also
oxid
stress
excitatori
amino
acid
product
proteosom
damag
could
secondari
augment
infect
substantia
nigra
microglia
activ
ip
secret
dopaminerg
neuron
express
receptor
upregul
nuclear
factor
apoptot
pathway
basal
ganglia
cerebrospin
fluid
csf
concentr
rais
cytotox
tlymphocyt
seen
relat
degener
nigral
dopaminerg
neuron
show
igg
bind
neuron
appear
label
destruct
proport
less
severelongerstand
diseas
activ
microglia
persist
presum
continu
mediat
damag
ip
activ
marker
circul
tlymphocyt
csf
monocyt
blood
csf
tcell
increas
bias
toward
bacteri
antigen
eg
heatshock
protein
associ
autoimmun
condit
promin
gutassoci
lymphoid
tissu
csf
contain
antibodi
bacteri
heatshock
protein
csf
blood
contain
antibodi
sympathet
dopaminerg
neuron
csf
ip
proband
recogn
rat
nigral
dopaminerg
neuron
inject
purifi
igg
ip
serum
rat
nigra
select
destroy
dopaminerg
neuron
purifi
igg
proband
csf
serum
toxic
cultur
toxic
depend
complement
microgli
antibodi
receptor
serum
ip
proband
also
inhibit
highaffin
neuron
dopamin
uptak
gammaamino
butyr
acid
uptak
underli
viral
infect
pandem
enceph
lethargica
spark
viral
hypothesi
parkinson
occur
uncompl
hiv
infect
precipit
opportunist
infect
eg
toxoplasmosi
acquir
immunodefici
syndrom
hiv
sensit
antidopaminerg
medic
parkinsonian
featur
may
associ
hiv
dementia
motor
dysfunct
compat
basal
ganglia
damag
found
earli
hiv
basal
ganglia
dopaminerg
cell
loss
seen
without
clinic
parkinson
simian
immunodefici
virusinfect
monkey
nigrostriat
dopamin
halv
within
month
seborrh
dermat
associ
ip
hiv
although
epidemiolog
hiv
distinct
rel
benign
retroviru
could
pathogen
ip
lewi
bodi
report
hiv
well
lymphopenia
damag
enter
nervou
system
ip
might
viral
origin
jejun
autonom
denerv
describ
hiv
infect
enterovirus
infect
via
gastrointestin
mean
confid
interv
shown
p
c
match
age
gender
p
predict
probabl
ps
cf
c
cs
combin
tract
associ
neurolog
syndrom
combin
virolog
approach
need
current
standardofcar
diagnost
assay
address
clinic
featur
ip
tabl
pathogen
discoveri
uncharacter
virus
antimicrobi
medic
could
produc
benefit
independ
elimin
target
organ
rat
minocyclin
reduc
inflamm
bloodbrainbarri
permeabl
dopaminerg
neuron
damag
produc
intranigr
inject
bacteri
lipopolysaccharid
tabl
outlin
strategi
approach
etiolog
pathogenesi
investig
medicin
yield
clinic
clue
elucid
process
mechan
pinpoint
system
natur
ip
ignor
templat
intervent
dogma
cold
neurodegener
demand
constitut
ill
attribut
caus
onestep
pragmat
rather
exploratori
strategi
mode
eg
eleg
patholog
studi
tabl
strategi
approach
etiologypathogenesi
idiopath
parkinson
step
back
consid
whole
entiti
reject
divid
syndrom
clinic
minutia
natur
cellular
protein
aggreg
defin
clinic
syndrom
awar
overlap
diseas
assembl
raw
clinic
clue
without
select
avoid
focus
tip
iceberg
diseas
long
prodrom
earli
diseas
may
hold
clue
mask
later
stage
inde
solut
may
unten
without
acknowledg
preclin
state
question
adequaci
measur
methodolog
reject
subject
global
score
embrac
valid
sensitivespecif
reliabl
measur
object
possibl
diseas
facet
identifi
clinic
relev
chang
time
intervent
adopt
exploratori
statist
methodolog
hypothesi
gener
defer
pragmat
test
seek
explain
clue
associ
measur
potenti
biolog
effect
small
welldefin
subject
group
take
account
candid
confound
effect
modifi
care
select
control
group
avoid
conveni
famili
includ
spous
close
contact
collect
observ
data
gener
statist
model
focus
differ
clue
address
differ
question
identifi
associ
effect
adjust
multipl
comparison
inappropri
fals
posit
anathema
stage
fail
notic
fals
reject
lead
retain
oddbal
result
pend
futur
insight
avoid
peer
pressur
conform
demand
repetit
seek
coher
explan
associ
clinic
clue
look
biolog
plausibl
explan
connect
identifi
piec
appear
fit
present
conundrum
divers
expert
gain
fresh
insight
conduct
pragmat
studi
testabl
causeeffect
hypothesi
gener
obtain
case
studi
evid
appropri
intervent
licens
treat
suspect
etiolog
agent
ie
explor
new
indic
proceed
perprotocol
analysi
random
efficaci
studi
effect
facet
syndrom
novel
intervent
need
seek
pharmaceut
collabor
appli
stage
pharmaceut
test
candid
compound
view
licens
defin
chain
event
natur
histori
elucid
process
mechanist
defin
hierarch
order
intervent
establish
case
tailor
optim
treatment
individu
screen
test
plan
prophylaxi
earli
clinic
syndrom
preclin
state
identifi
core
event
perpetu
circumst
perform
effect
studi
avail
intervent
use
environmentallygenet
heterogen
subject
group
larg
sampl
size
outcom
criteria
appropri
effect
studi
use
intentiontotreat
analysi
give
generaliz
result
benefit
continu
explor
differenti
effect
intervent
perprotocol
analys
challeng
robust
hypothesi
suggest
refin
document
advers
event
predictor
control
introduct
clinic
practic
initi
surveil
program
b
alert
unmask
etiolog
insight
unanticip
advers
event
long
term
allow
economi
sampl
size
give
clariti
defin
differenti
time
trend
diseas
facet
allow
preand
postpresent
state
consid
continuum
diseas
wide
accept
long
prodrom
global
score
even
relev
subscor
rel
insensit
intervent
ad
immut
mask
import
chang
b
requir
evid
beyond
reason
doubt
clinic
import
discoveri
h
pylori
see
ip
evolv
gastrointestin
tract
reader
seiz
upon
one
mechan
migrat
along
neural
pathway
assess
ip
global
subject
score
ubiquit
analog
studi
diabet
mellitu
without
blood
glucos
cardiovascular
risk
factor
financi
constraint
risk
associ
innov
mean
field
replough
tradit
fund
favor
laboratorytoclin
approach
arbitrari
select
put
pathogen
mechan
detail
examin
direct
patch
damag
eg
seek
modifi
compon
cellular
mechan
replacerestor
dopaminerg
neuron
surgic
implantsintracerebr
infus
neurotrophin
rather
get
grip
might
drive
process
dissoci
unwis
ongo
inflamm
may
jeopard
patchingup
work
fund
initi
medic
research
council
subsequ
psychiatri
research
trust
receiv
grant
hayward
foundat
cyril
corden
trust
cecil
pilkington
charit
trust
donat
abbott
laboratori
astrazeneca
barclay
corpor
social
respons
ambassador
nichola
smith
coordin
fundrais
program
malcolm
plant
coordin
network
support
patient
carer
dr
ron
hutton
help
bibliographi
review
dedic
memori
anthoni
dawson
paul
